Biogen-Funded Collaboration with Americares and Harvard Chan C-CHANGE Recognized by the Clinton Global Initiative
在美国，气候危机威胁着成千上万的社区卫生中心的能力，以照顾数百万未保险或保险不足的患者。188bet网址怎么打不开为了解决与气候有关的操作和患者健康的风险，Biogen正在与Americaresand the Center for Climate, Health, and the Global Environment at Harvard T.H. Chan School of Public Health (Harvard Chan C-CHANGE). This week, theClinton Global Initiativerecognized the commitment made through this partnership and the global expansion of the program with theHarvard Global Health Institute.
Together, the organizations are creating afirst-of-its-kind Climate Resilient Health Clinics Toolkitthat will help clinics use available resources to better manage patient care when facing increasingly common climate health effects. A toolkit module on extreme heat has already been rolled out to pilot clinics. Modules on wildfires and hurricanes will follow later this year.
Biogen’s support for the program is part of its健康的气候，健康的生活™initiative, the company’s groundbreaking 20-year, $250 million initiative to address climate, health and equity. The commitment aims to eliminate fossil fuel emissions across business operations by 2040, engage employees and suppliers, and collaborate with renowned institutions to advance the science and action to improve health outcomes.
About Biogen
As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has a leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and developed the first and only approved treatment to address a defining pathology of Alzheimer’s disease. Biogen is also commercializing biosimilars and focusing on advancing one of the industry’s most diversified pipelines in neuroscience that will transform the standard of care for patients in several areas of high unmet need.
We routinely post information that may be important to investors on our website atwww.biogen.com. Follow us on social media -Twitter,LinkedIn,Facebook,YouTube.
